Targeted therapies in breast cancer: Established drugs and recent developments

Current Clinical Pharmacology

Volumn 3, Issue 2, 2008, Pages 85-98

  Fischgräbe, Jeanett ^a   Wülfing, Pia ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Atrasentan; Breast cancer; Endothelin receptor A; Small molecule inhibitors; Targeted therapies

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CANERTINIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; ERLOTINIB; EVEROLIMUS; EXEMESTANE; FLAVOPIRIDOL; FULVESTRANT; GEFITINIB; GEMCITABINE; LAPATINIB; LETROZOLE; NAVELBINE; OBLIMERSEN; PACLITAXEL; PERTUZUMAB; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; ENDOTHELIN A RECEPTOR; TUMOR PROTEIN;

AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RESISTANCE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DESQUAMATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; THROMBOCYTOPENIA; BREAST TUMOR; DRUG DELIVERY SYSTEM; DRUG EFFECT; FEMALE; GENETICS; PATHOLOGY; PROTO ONCOGENE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; FEMALE; GENES, ERBB-2; HUMANS; NEOPLASM PROTEINS; RECEPTOR, ENDOTHELIN A;

EID: 52049098991     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488408784293732     Document Type: Review

References (180)

1. Globocan 2002: cancer incidence, mortlity and prevalence worldwide. Version 2.0. International Agency for Research on Cancer 2005.
2. Surveillance, Epidemiology, and End Results (SEER) Database. Available at: http://www.seer.cancer.gov/statfacts/html/breast.html (accessed December 5, 2006)
3. Peto J, Mack TM. High contrast incidence in twins and other relatives of women with breast cancer. Nature 2000; 26: 411-4.
4. Gomez H, Chavez M, Doval D, et al. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 2005; 23: abstract 3046.
5. Miller KD, Burstein HJ, Elias A, et al. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2005 (abstr); 23: 563.
6. Forbes JF. The control of breast cancer: the role of tamoxifen. Semin Oncol 1997; 24: S1-5 (S1-19).
7. Gradishar WJ. Tamoxifen-what next? Oncologist 1998; 9: 378-84.
8. DeFriend DJ, Anderson E, Bell J, et al. Effects of 4-hydroxytamoxifen and a novel pure antiestrogen (ICI 182780) on clonogenic growth of breast cancer cells in vitro. Br J Cancer 1994; 70: 204-11.
9. Ali S, Coombes RC. Endocrine responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2: 101-12.
10. Baum M, Budzar AU, Cuzick J, et al. ATAC trialists' group: anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-39.
11. Ferretti G, Bria E, Giannarelli D, et al. Second and third generation aromatase inhibitors as first line therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. Br J Cancer 2006; 94: 1789-96.
12. ATAC Trialists' group. Results of the ATAC (Arimidix, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-2.
13. Thurlimann B, Keshaviah A, Coates AS, et al. Breast international group (BIG) I-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353 (26): 2747-57
14. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-92.
15. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-positive Breast Cancer: Status Report 2004. J Clin Oncol 2005; 23 (3): 619-29.
16. Goldhirsch JH, Glick RD, Gelber AS, Coates B, Thürlimann, Senn H-J and Panel Members Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol 2005; 16: 1569-1583.
17. Jeng MH, Shupnik MA, Bender TP, et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998; 139: 4164-74.
18. Martin L-A, Farmer I, Johnston SRD, Ali S, Marshall C, Dowsett M. Enhanced ER-alpha; ERB2, MAPK signal transduction pathways operate during the adaption of MCF-7 cells to long-term estrogen deprivation. J Biol Chem 2003; 278: 30458-68.
19. Perey L, Paridaens R, Hawle H, et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007; 18: 64-9.
20. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235: 177-82.
21. Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002; 20(6): 1467-72.
22. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenetic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523-30.
23. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-6.
24. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21: 2889-95.
25. O'Shaughnessy JA, Vukelja S, Marsland T, et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 2004; 5: 142-7.
26. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1673-84.
27. Pegram MD, Konecny GE, O'Callaghan C, et al. Rationale combination of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96: 739-49.
28. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11): 783-92.
29. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: M77001 study group. J Clin Oncol 2005; 23(19): 4265-74.
30. Slamon DJ, Eiermann W, Robert NJ, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamid followed by docetaxel (AC-T) with doxorubicin and cycophosphamid followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin, and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. 28th Annual San Antonio Breast Cancer Symposium 2005. San Antonio, TX, USA: abstract 1.
31. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1659-72.
32. Nahta R, Takahashi T, Ueno NT, et al. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004; 64: 3981-86.
33. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-27.
34. Lu Y, Zi X, Pollak M. Molecular mechanism underlying IGF-I induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 2004; 108: 334-41.
35. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
36. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003; 200: 290-7.
37. Travis A, Pinder SE, Robertson JF, et al. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer 1996; 74: 229-33.
38. Tovey SM, Witton CJ, Barlett JM, Stanton PD, Reeves JR, Cooke TG. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labeling. Breast Cancer Res 2004; 6: R246-51
39. Spicer J. Technology evaluation: pertuzumab, Roche/Genentech/Chugai. Curr Opin Mol Ther 2004; 6(3): 337-43.
40. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64 (7): 2343-46.
41. Clinical trials. gov. A service of the U.S. National Institutes of Health, developed by the National Library of Medicine. Available at: http://clinicaltrials.gov (accessed December 5, 2006)
42. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel her dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23(11): 2534-43.
43. Cortes J, Baselga J, Kellokumpu-Lehtinen P, et al. Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2. Proc Am Soc Clin Oncol 2005; 23: abstract 3068.
44. du Manoir JM, Francia G, Man S, et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006; 12(3 Pt 1): 904-16.
45. Li X, Luwor R, Lu Y, Liang K, Fan Z. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene 2006; 25(4): 525-35.
46. Modi S, D'Andrea G, Norton L, et al. A phase I study of cetuximab/ paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 2006; 7(3): 270-7.
47. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66 (3): 1630-39.
48. Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005; 24(41): 6213-21.
49. Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005; 65(1): 18-25.
50. Versola M, Burris HA 3rd, Jones S, et al. Clinical activity of GW-572016 in EGF-1003in patients with solid tumors. Proc Am Soc Clin Oncol 2004; 22: abstract 3047.
51. Burris HA 3rd, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (gw-572016), a reversible, dual inhibitor of epidermal growth factor receptor tyrosine kinases in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23(23): 5305-13.
52. Blackwell KL, Kaplan EH, Franco SX, et al. A phase II, open-label, multi-center study of GW-572016 in patients with trastuzumab-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 2005; 23: abstract 3004
53. Geyer CE, Cameron D, Lindquist S, et al. A randomized, open-label, international study comparing lapatinib and capecitabine in women with refractory advanced or metastatic breast cancer (EGF100151). ASCO 2006.
54. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005; 23(23): 5323-33.
55. Albain K, Elledge R, Gradishar WJ, et al. Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 2002; 76 (Suppl 1): abstract 20.
56. Robertson JFR, Gutteridge E, Cheung KL, et al. Gefitinib (ZD1839) is active in required tamoxifen-resitant oestrogen receptor and ER-negative breast cancer: results from a phase II study. Proc Am Soc Clin Oncol 2003; 22: abstract 23.
57. Winer E, Cobleigh M, Dickler M, et al. Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2002; 76 (Suppl. 1): abstract 445.
58. Calvo E, Tolcher AW, Hammond LA, et al. Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study. Clin Cancer Res 2004; 10(21): 7112-20.
59. Campos S, Hamid O, Seiden MV, et al. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol 2005; 23(24): 5597-604.
60. Nemunaitis J, Eiseman I, Cunningham C, et al. Phase I clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res 2005; 11(10): 3846-53.
61. Simon GR, Garrett CR, Olson SC, et al. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res 2006; 12(15): 4645-51.
62. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000; 102; 1-4.
63. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15; 2922-33.
64. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281(5381): 1322-6.
65. Bartke T, Siegmund D, Peters N, et al. p53 upregulates cFLIP, inhibits transcription of NF-κB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 2001; 20: 571-80.
66. Wu Y, Mehew JW, Heckman CA, Arcinas M, Boxer LM. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 2001; 20: 240-51.
67. Stambolic V, MacPherson D, Sas D, et al. Regulation of PTEN transcription by p53. Mol Cell 2001; 8: 317-25.
68. Moroni MC, Hickman ES, Denchi EL, et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 2001; 3: 552-8.
69. Ryan KM, Phillips AC, Vousden KH. Regulation and function of p53 tumor suppressor protein. Curr Opin Cell Biol 2001; 13: 332-7.
70. Tschopp J, Martinon F, Hofmann K. Apoptosis: silencing the death receptors. Curr Biol 1999; 9: R381-4.
71. Reed JC. Apoptosis and cancer: strategies for integrating programmed cell death. Semin Hematol 2000; 37: 9-16.
72. Makin G, Hickmann JA. Apoptosis and cancer chemotherapy. Cell Tissue Res 2000; 301: 143.
73. Polyak K. The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty? Cancer Cell 2006; 10(5): 352-4.
74. Boulay A, Rudolff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Can Res 2005; 11(4): 5319-28.
75. Chollet P, Abrial C, Tacca O, et al. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer 2006; 7(4): 336-8.
76. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23(23): 5314-22.
77. Placios C, Yerbes R, Lopez-Rivas A. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res 2006; 66(17): 8858-69.
78. Najmi S, Korah R, Chandra R, Abdellatif M, Wieder R. Flavopiridol blocks integrin-mediated survival in dormant breast cancer cells. Clin Cancer Res 2005; 11(5): 2038-46.
79. Tan AR, Yang X, Berman A, et al. Phase I trial of cyclin-dependent kinase inhibitor falvopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res 2004; 10(15): 5038-47.
80. Koh J, Kubota T, Koyama T, et al. Combined antitumor activity of 7-hydroxystaurosporine (UCN-01) and tamoxifen against human breast carcinoma in vitro and in vivo. Breast cancer 2003; 10(3): 260-7.
81. Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology 1999; 54(6A Suppl): 36-46.
82. Marshall J, Chen H, Yang D, et al. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 2004; 15(8): 1274-83.
83. Meidan VM, Glezer J, Salomon S, et al. Specific lipoplex-mediated antisense against Bcl-2 in breast cancer cells: a comparison between different formulations. J Liposome Res 2006; 16(1): 27-43.
84. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999; 80(12): 1968-73.
85. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer 2006; 13(2): 293-325.
86. Engers R, Gabbert HE. Mechanism of tumor metastasis: cell biological aspects and clinical implications. J Cancer Res Clin Oncol 2000; 126: 682-92.
87. Gabbert H, Wagner R, Moll R, Gerharz CD. Tumor dedifferentiation: an important step in tumor invasion. Clin Exp Metastasis 1985; 3: 257-79.
88. Crawford HC, Matrisian LM. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 1994; 14: 234-45.
89. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumor invasion, metastasis and angiogenesis. Eur Respir J 1994; 7: 2062-72.
90. Nielsen LS, Kellerman GM, Behrendt N, et al. A 55,000 60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem 1988; 263: 2358-63
91. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269: 15957-60.
92. Jänicke F, Schmitt M, Pache L, et al. Urokinase plasminogen activator (uPA) and its inhibitor PAI-1are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993; 24: 135-44.
93. Duffy MJ, Reilly D, O'Sullivan C, et al. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990; 50: 6827-9.
94. Maquoi E, Sounni NE, Devy L, et al. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res 2004; 10(12 Pt 1): 4938-47.
95. Sparano JA, Bernardo P, Stephenson P, et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004; 22(23): 4683-90.
96. Zucker S, Wang M, Sparano JA, Gadishar WJ, Ingle JN, Davidson NE. Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196. Clin Breast Cancer 2006; 6 (6): 525-9.
97. Ertongur S, Lang S, Mack B, Wosikowski K, Muehlenweg B, Gires O. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer 2004; 110(6): 815-24.
98. Setyono-Han B, Sturzebecher J, Schmalix WA, et al. Suppression of rat breast cancer metastasis and reduction of primary tumor growth by small synthetic urokinase inhibitor WX-UK1. Thromb Haemost 2005; 93(4): 779-86.
99. Folkman J. Tumorangiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-86.
100. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333(26): 1757-63.
101. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 1996; 56: 2013-16.
102. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993; 4(12): 1317-26.
103. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000; 5 (Suppl 1): 37-44.
104. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26(1): 86-91.
105. Wu Y, Hooper AT, Zhong Z, et al. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer 2006; 119: 1519-29.
106. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2001; 12(3): 129-35.
107. Wulfing P, Kersting C, Buerger H, et al. Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer 2005; 92(9): 1720-8.
108. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57(20): 4593-9.
109. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-42.
110. Johnson DH, Fehrenbacher L, Nowotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22(11): 2184-91.
111. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30(5 Suppl 16): 117-24.
112. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23(4): 792-9.
113. Miller KD, Wang M, Gralow J, et al. E2100: a randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Proc Am Soc Clin Oncol 2005: 23; abstract 3019.
114. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU-11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 5(5): 471-78.
115. Mendel DB, Laird AD, Xin X, et al. in vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-37.
116. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20: 757-66.
117. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003; 2(10): 1011-21.
118. Huang X, Wong MK, Yi H, et al. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res 2002; 62(20): 5727-35.
119. Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 2002; 8(9): 2798-805.
120. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62(16): 4645-55.
121. Miller KD, Trigo JM, Wheeler C, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005; 11(9): 3369-76.
122. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189-218.
123. Yan J, Roy S, Apollini A, Lane A, Hancock JF. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 1998; 273: 24052-6.
124. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417(6892): 949-54.
125. Bos JL. Ras oncogenes in human cancer: A review. Cancer Res 1989; 49: 4682-4689.
126. Warnberg F, Withe D, Anderson E, et al. Effect of farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in human xenografts model and on breast and ovarian cancer cell growth in vitro and in vivo. Breast Cancer Res 2006; 8(2): R21.
127. Kelland LR, Smith V, Valenti M. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 2001; 7(11): 3544-50.
128. Dalenc F, Giamarchi C, Petit M, Poirot M, Favre G, Faye JC. Farnesyl-transferase inhibitor R115777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways. Breast Cancer Res 2005; 7(6): R1159-67.
129. Izbicka E, Campos D, Carrizales G, Patnaik A. Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro. Anticancer Res 2005; 25(5): 3215-23.
130. Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003; 21(13): 2492-9.
131. Sparano JA, Moulder S, Kazi A, et al. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J Clin Oncol 2006; 24(19): 3013-8.
132. Lebowitz PF, Eng-Wong J, Widemann BC. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. Clin Cancer Res 2005; 11(3): 1247-52.
133. Garnett MJ, Marais R. Guilty as charged: B-Raf is a human oncogene. Cancer Cell 2004; 6: 313-9.
134. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64(19): 7099-109.
135. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23(5): 965-72.
136. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92(10): 1855-61.
137. Eisen T, Bukowski RM, Staehler M, et al. For The Sorafenib TARGETs Clinical Trial Group. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. Proc Am Soc Clin Oncol 2006; 24: abstract 4524.
138. Loibl S, Bianch G, Zamagni C, et al. Sorafenib (BAY 43-9006) in patients with metastatic breast cancer - a Phase II multicentre open trial. German Med Sci 2006; Doc PO032.
139. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994; 46: 325-415.
140. Simonson MS. Endothelins: multifunctional renal peptides. Physiol Rev 1993; 73: 375-411.
141. Shichiri M, Hirata Y, Nakajima T, et al. Endothelin-1 is an autocrine/paracrine growth factor for humancancer cell lines. J Clin Invest 1991; 87: 1867-71.
142. Bagnato A, Catt KJ. Endothelins as autocrine regulators of tumor cell growth. Trends Endocr Metab 1998; 9: 378-83.
143. Salani D, Di Castro V, Nicotra MR, et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 2000; 157(5): 1537-47.
144. Nelson JB, Udan MS, Guruli G, Pflug BR. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 2005; 7(7): 631-7.
145. Shankar A, Loizidou M, Aliev G, et al. Raised endothelin 1 levels in patients with colorectal liver metastases. Br J Surg 1998; 85(4): 502-6.
146. Wulfing P, Diallo R, Kersting C, et al. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin Cancer Res 2003; 9(11): 4125-31.
147. Wulfing P, Kersting C, Tio J, et al. Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. Clin Cancer Res 2004; 10(7): 2393-400.
148. Hagemann T, Binder C, Binder L, Pukrop T, Trumper L, Grimshaw MJ. Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol 2005; 24(11): 766-76.
149. Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR. A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res 2004; 64(7): 2461-8.
150. Salani D, Rosano L, Di Castro V, et al. ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro. Clin Sci (Lond) 2002; 103(Suppl 48): 318S-321S.
151. Rosano L, Spinella F, Salani D, et al. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 2003; 63(10): 2447-53.
152. Okazawa M, Shiraki T, Ninomiya H, Kobayashi S, Masaki T. Endothelin-induced apoptosis of A375 human melanoma cells. J Biol Chem 1998; 273(20): 12584-92.
153. Rajeshkumar NV, Rai A, Gulati A. Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats. Breast Cancer Res Treat 2005; 94(3): 237-47.
154. Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ, McGuire WL. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst 1993; 85(7): 570-4.
155. Cornford PA, Dodson AR, Parsons KF, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000; 60(24): 7099-105.
156. Blagosklonny MV. Re: Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2001; 93(3): 239-40.
157. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347(25): 1999-2009.
158. Beckmann RP, Mizzen LE, Welch WJ. Interaction of Hsp 70 with newly synthesized proteins: implications for protein folding and assembly. Science 1990; 248(4957): 850-4.
159. Freeman BC, Yamamoto KR. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 2002; 296(5576): 2232-5.
160. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001; 61(10): 4003-9.
161. Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res 2003; 9(13): 4961-71.
162. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003; 63(9): 2139-44.
163. Price JT, Quinn JM, Sims NA. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005; 65(11): 4929-38.
164. Banerji U, O'Donnell A, Scurr M. Phase I pharmacokinetic and
165. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H: quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol Pharmacol 2006; 70(4): 1194-203.
166. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4(7): 505-18.
167. O'Gorman DB, Weiss J, Hettiaratchi A, Firth SM, Scott CD. Insulin-like growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo. Endocrinology 2002; 143(11): 4287-94.
168. De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/ insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995; 10(9): 1725-9.
169. Hankins GR, De Souza AT, Bentley RC, et al. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 1996; 12(9): 2003-9.
170. Ouyang H, Shiwaku HO, Hagiwara H, et al. The insulin-like growth factor II receptor gene is mutated in genetically unstable cancers of the endometrium, stomach, and colorectum. Cancer Res 1997; 57(10): 1851-4.
171. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/ insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002; 277(42): 39684-95.
172. Sciacca L, Costantino A, Pandini G, et al. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/ paracrine mechanism. Oncogene 1999; 18(15): 2471-9.
173. Maloney EK, McLaughlin JL, Dagdigian NE, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63(16): 5073-83.
174. Burtrum D, Zhu Z, Lu D, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63(24): 8912-21.
175. Wang Y, Hailey J, Williams D, et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 2005; 4(8): 1214-21.
176. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 2003; 63(3): 627-35.
177. Garcia-Echeverria C, Pearson MA, Marti A, et al. in vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5(3): 231-9.
178. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5(3): 221-30.
179. Gable KL, Maddux BA, Penaranda C, et al. Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol Cancer Ther 2006; 5(4): 1079-86.
180. Haluska P, Carboni JM, Loegering DA, et al. in vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/ insulin receptor inhibitor, BMS-554417. Cancer Res 2006; 66(1): 362-71.